Engineered immune cells take aim at Hard-to-Treat lymphoma
NCT ID NCT01192464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a special receptor that targets the CD30 protein found on lymphoma cells, and also train them to recognize the common EBV virus to help them last longer in the body. The main goal is to check the safety of these modified cells and see if they can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Supercharged immune cells take aim at cancer and viruses in one shot
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Gut bacteria may hold key to chemo side effects
- Engineered t cells take on lymphoma in early trial
- New 'In-Body' CAR-T therapy takes aim at Hard-to-Treat lymphoma
- Experimental 'In-Situ' vaccine aims to train immune system against three cancers